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INTRODUCTION
The term targeted therapies refers to treatment strategies directed against 
molecular targets that are involved in the process of neoplastic trans-
formation. In the second half of the twentieth century, cancer treatment 
options evolved with more sophisticated selection of targets for cancer 
therapy, which led to the development of more intelligent drugs directed 
against these specific targets (1). One group of molecular targeted agents 
is monoclonal antibodies (mAbs). 
The purpose of this study was to show the expenditure of mAbs at the 
Oncology Institute of Vojvodina from 2007 to 2011. Next, to display the 
number of patients treated with mAbs, for each indication.
MATERIAL AND METHODS
From 2007, we use software programs Lirpis and LWM for the purposes 
of monitoring supply, distribution, and drug expenditure at our Institute. 
These programs were used for collecting data regarding mAbs expendi-
ture during 5-year period, from April 2007 to the end of 2011. 
The comments about the situation in our country regarding the indications 
for mAbs were given with the review on the FDA approvals (Table 1).
RESULTS
The use of mAbs at the Oncology Institute of Vojvodina began in 2005. 
The first one that became available for the treatment was rituximab, fol-
lowed by the use of trastuzumab. The expenditure of mAbs during the 
5-year period was expressed by the number of ampoules dispensed from 
hospital pharmacy each year, respectively.
Figure 1 shows the increase in number of ampoules dispensed from 
the pharmacy from 2007 to 2010, and a slight decrease in 2011 for all 
monoclonal antibodies. 
Figure below shows the total number of patients treated with each mAbs. In 
addition, it displays number of hospital contacts that include therapy with cer-
tain mAbs, necessary for calculating the average number of therapy cycles.
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SUMMARY
Background: In the second half of the twentieth century, cancer treatment options evolved with more sophisticated 
selection of targets for cancer therapy, which led to the development of more intelligent drugs directed against these 
specific targets. One group of pharmaceutical molecules with specific and unique properties against (or for) a well-
defined molecular target is monoclonal antibodies (mAbs). The purpose of this study was to show the expenditure of 
mAbs at the Oncology Institute of Vojvodina from 2007 to 2011. Next, to display the number of patients treated with 
mAbs and therapy cycles, for each indication.
Methods: We used software programs Lirpis and LWM for collecting the data regarding mAbs expenditure from April 
2007 to 2011. The comments about the situation in Serbia were given with the review on the FDA approvals.
Results: The results showed the increase in number of ampoules dispensed from the pharmacy from 2007 to 2010, 
and a slight decrease in 2011 for all mAbs. With 4070 vials of rituximab, 195 patients were treated. The average number 
of therapy cycles was 7.34. With total number of 4341 of trastuzumab, we treated 310 patients, with average number 
of cycles 12.27. With 1343 ampoules of bevacizumab, we treated 92 patients. The average number of cycles was 6.63. 
With 7051 ampoules of cetuximab, we treated 94 patients, with average number of therapy cycle of 5.94.
Conclusion: Despite proven benefits of mAbs for many other indications according to FDA, in our Institution (based on 
the indications approved by Republic Institute of Health Insurance), bevacizumab, and cetuximab are used for colorec-
tal cancer, trastuzumab is only used for breast cancer and rituximab for non-Hodgkin lymphoma. The decrease of the 
number of ampoules dispensed from our pharmacy and the number of patients in 2011 was caused by tightening the 
criteria indications by Republic Institute of Health Insurance.
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Figure 1. Number of ampoules dispensed from pharmacy each year from April 2007 to 201154
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Therapy cycles were calculated by dividing the number of hospital con-
tacts that included MA therapy with the number of patients. Results are 
shown in the Table 2.
Table 2. Number of ampoules, patients, and therapy cycles for the 5-year period
No of ampoules No of patients No. of therapy cycles
Rituximab 4070 195 7.34
Trastuzumab 4341 310 12.27
*Bevacizumab 1343 92 6.63
*Cetuximab 7051 94 5.94
*Bevacizumab and cetuximab were not available in 2007. The results are shown from 2008 to 2011.
DISCUSSION
There are three potential approaches to attack a membrane receptor:
•  Neutralization of the ligand
•  Competitive inhibition of ligand–receptor engagement
•  Inhibition of transduction of the signal from the receptor to secondary 
cytoplasmic messengers (1). 
The first target for intervention in a signaling cascade is the neutralization 
of ligands before they can associate with their receptors. This approach 
has been successfully validated with bevacizumab, a humanized mono-
clonal antibody targeting circulating vascular endothelial growth factor 
(VEGF) (2).
Table 1. FDA approvals for mAbs
Date of approval Indication
Bevacizumab February 2004
June 2006
October 2006
February 2008*
May 2009
July 2009
First-line treatment of metastatic colorectal cancer
Second line treatment of metastatic colorectal cancer in combination with i.v 5-fluorouracil based chemotherapy
Initial systemic treatment of unresectable, locally advanced, recurrent, or metastatic, non-squamous, non-small cell lung 
cancer in combination with carboplatin and paclitaxel
Metastatic breast cancer
Single agent for progressive glioblastoma following prior therapy
Metastatic renal cell carcinoma in combination with interferon alfa
Cetuximab February 2004
March 2006 
November 2011
July 2012
EGFR-expressing, metastatic colorectal carcinoma in combination with irinotecan in patients who are refractory to 
irinotecan-based chemotherapy
EGFR-expressing, recurrent metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy
Locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) in combination with radiation or 
as a single agent for the treatment of recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed
First-line treatment of recurrent locoregional disease and/or metastatic SCCHN in combination with platinum-based 
therapy plus 5-florouracil 
First-line treatment of patients with K-ras mutation-negative EGFR-expressing metastatic colorectal cancer in 
combination with FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) 
Trastuzumab November 2006
October 2010
Adjuvant treatment of women with node-positive, HER2-overexpressing breast cancer as a part of a treatment regimen 
containing doxorubicin, cyclophosphamide, and paclitaxel 
For the treatment of HER2-overexpressing metastatic gastric or gastroesophegal (GE) junction adenocarcinoma who 
have not received prior treatment for metastatic disease, in combination with cisplatin and a fluoropyrimidine (either 
capecitabine or 5-fluorouracil)
Rituximab February 2006
September 2006
February 2010
January 2011
First-line treatment of diffuse large B-cell, CD20-positive, non-Hodgkin’s lymphoma in combination with 
cyclophosphamide, doxorubicin, vincristine and prednisone or other anthracycline-based chemotherapy regimens
First-line treatment of patients with low grade or follicular B-cell, CD20-positive non-Hodgkin’s lymphoma
Treatment of both previously untreated and previously treated chronic lymphocytic leukemia in combination with 
fludarabine and cyclophosphamide (FC) 
Maintenance therapy for previously untreated follicular CD-20 positive B-cell non-Hodgkin lymphoma who achieve a 
response to rituximab in combination with chemotherapy
* On November 18, 2011, Food and Drug Administration Commissioner revoked the agency’s accelerated approval of the breast cancer indication for bevacizumab because it did not show to provide a benefit.
Figure 2. Total number of patients and hospital contacts from 2007 to 201155
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Bevacizumab is derived from the parent murine anti-VEGF MAb (3). It 
binds to all major human isoforms of VEGF (also known as VEGF-A) 
(4). Bevacizumab binding to VEGF prevents VEGF from binding to the 
VEGF receptor (VEGF receptor-1 and VEGF receptor-2) on vascular 
endothelial cells, thus preventing VEGF-mediated signaling and inhibiting 
tumor angiogenesis. This ultimately leads to a reduction in microvascular 
growth, inhibits progression of metastatic disease, and reduces intratu-
moral pressure, which may improve the delivery of cytotoxic agents (5, 
6). Furthermore, in the absence of VEGF signals, endothelial cells become 
fragile and susceptible to apoptosis. The cells rupture and vessels bleed, 
resulting in reduced blood flow and vessel regression (7, 8). Bevacizumab 
has shown benefits in advanced nonsquamous non–small cell lung 
cancer (NSCLC) in combination with carboplatin and paclitaxel in people 
who have not received chemotherapy for their advanced disease (9), in 
patients with metastatic kidney cancer (mRCC) when used with interferon 
alfa (10), and in glioblastoma (GBM) in adult patients whose cancer has 
progressed after prior treatment (11, 12). However, in Serbia, bevaci-
zumab is only approved for colorectal, metastatic, potentially resectable 
cancer, predominant in liver, in the clinical stage IVB or IVC as the first line 
systemic treatment in combination with chemotherapy until the resect-
ability of metastasis is achieved and with maximum of 10 therapy cycles.
As a second option, direct inhibition of ligand–receptor engagement 
can be achieved by preventing the binding of the growth factors to their 
receptors by mimicking the ligand’s structure and interfering thus in the 
ligand–receptor affinity. A proof of this concept is cetuximab, a chimeric 
antibody against the epidermal growth factor receptor (EGFR) (13). 
Trastuzumab activity against the HER2 receptor is also a clear, successful 
approach (14). 
Epidermal growth factor receptor (EGFR), a member of the ErbB fam-
ily of receptors, is relevant in colorectal cancer because the expression 
or upregulation of the EGFR gene occurs in 60 to 80 percent of cases 
(15-17). Moreover, expression of the gene is associated with poor sur-
vival (18, 19). When inactive, EGFR is a monomer, but when bound by 
epidermal growth factor or transforming growth factor α (TGF-α), it 
forms homodimers or heterodimers with another member of the ErbB 
family of receptors. Dimerization activates the intracellular tyrosine kinase 
region of EGFR, resulting in autophosphorylation and initiating a cascade 
of intracellular events (20). The EGFR signaling pathway regulates cell 
differentiation, proliferation, migration, angiogenesis, and apoptosis, all 
of which become deregulated in cancer cells (21). Cetuximab, recom-
binant, human/mouse chimeric IgG1 monoclonal antibody, binds to 
extracellular domain of EGFR with high specificity and with a higher affin-
ity than either epidermal growth factor or TGF-α, thus blocking ligand-
induced phosphorylation of EGFR and activation of receptor-associated 
kinases, resulting in inhibition of cell growth, induction of apoptosis, 
and decreased matrix metalloproteinase and vascular endothelial growth 
factor production. The EGFR is constitutively expressed in many nor-
mal epithelial tissues, including the skin and hair follicle. Cetuximab 
is indicated for colorectal and squamous cell carcinomas of the head 
and neck (SCCHN) and for both is approved in our country. For meta-
static colorectal cancer, it is indicated after the chemotherapy based on 
oxaliplatin and irinotecan, for tumors with non-mutated K-ras gene, as 
monotherapy or in combination with irinotecan. For SCCHN it is used 
if the disease is locally advanced, inoperable, if radiotherapy was not 
indicated initially, after chemotherapy, in combination with radiotherapy. 
In addition, if the locally advanced disease is inoperable, cetuximab is 
used in combination with radiotherapy in patients when platinum-based 
therapy is contraindicated.
HER2 is a transmembrane tyrosine kinase receptor, which belongs to the 
family of the EGFR (epidermal growth factor receptor). It is overexpressed 
in 20%–30% of human breast cancers (22). Its unique feature, which 
differentiates it from the other members of the family, is the absence 
of a known ligand. It was reported that HER2 requires HER3 to drive 
breast cancer cell proliferation (23). Trastuzumab is a humanized mAb 
of the immunoglobulin G1 type directed against the extracellular portion 
of HER2 (24). Among proposed mechanisms of action is activation of 
antibody-dependent cellular cytotoxicity (ADCC) (25-27). ADCC is mainly 
due to the activation of natural killer cells (NK), expressing the Fc gamma 
receptor, which can be bound by the Fc domain of trastuzumab. This 
event activates the lysis of cancer cells bound to trastuzumab. Next, 
trastuzumab can block the shedding of the extracellular domain of HER2 
by inhibiting metalloproteinase activity. Trastuzumab also specifically 
inhibits phosphoinositide 3-kinase (PI3K) signaling, which in turn leads 
to inhibition of cell proliferation. Overexpression of HER2 in breast can-
cer cells is closely associated with increased angiogenesis. One of the 
trastuzumab mechanisms of action is inhibition of angiogenesis. Cells 
treated with trastuzumab undergo arrest during the G1 phase of the cell 
cycle, with a concomitant reduction in proliferation. ToGA study, which 
was the first randomized trial investigating anti-HER2 therapy in advanced 
gastric cancer showed that trastuzumab + chemotherapy is superior to 
chemotherapy alone. Despite the overall survival benefit proven in this 
study, trastuzumab is in Serbia indicated only for breast cancer (28). It 
is indicated if there is overexpression of HER2 gene after the adjuvant 
therapy with anthracyclines, as monotherapy or in combination with 
taxanes, to 12 months, in node positive and node negative patients 
with tumors larger then 10mm. For metastatic disease, it is the first 
line treatment after anthracycline therapy, in combination with taxanes, 
6 to 8 cycles, and in progression-free period trastuzumab is given as 
monotherapy until the progression. For locally advanced breast cancer, 
it is given in combination with taxane chemotherapy, after the previous 
sequential use of anthracyclines.
Rituximab is a chimeric antibody in which the variable antigen-binding 
part (Fab) directed against the CD20 antigen is of murine origin, and 
the constant part (Fc), important for the activation of human effector 
functions, is of human origin. The CD20 antigen is expressed abundantly 
on most normal B cells (but not on stem cells and plasma cells), and, 
importantly, on more than 90% of B cell lymphomas. It is an antigen that 
is neither shed nor modulated, making it a very suitable target for anti-
body therapy (29). Rituximab destroys B-cells by multiple mechanisms 
including complement-dependent cytotoxicity, antibody-dependent cel-
lular cytotoxicity, growth inhibition, and apoptosis (30). Despite proven 
benefits of rituximab in chronic lymphocytic leukemia (CLL), in Serbia it 
is approved only for non-Hodgkin lymphoma. It is indicated if the tumor is 
CD20 positive, for the subtype of diffuse large B cell lymphoma in newly 56
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diagnosed patients, in combination with chemotherapy. Rituximab is also 
indicated in subtype of follicular lymphoma, both in newly diagnosed and 
patients in relapse.
CONCLUSION
As shown in the results there was the increase in number of ampoules 
dispensed from the pharmacy from 2007 to 2010, and a slight decrease 
in 2011 for all monoclonal antibodies. The decrease of the number of 
ampoules dispensed from our pharmacy and the number of patients 
in 2011 is caused by tightening the criteria indications by the Republic 
Institute of Health Insurance.
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